Small-molecule inhibitor targeting orphan nuclear receptor COUP-TFII for prostate cancer treatment

Area of Science:

• Molecular biology
• Oncology
• Drug discovery

Background:

• The orphan nuclear receptor COUP-TFII is upregulated in diseases like prostate cancer, heart failure, and muscular dystrophy.
• COUP-TFII promotes disease progression, making it a potential therapeutic target.
• Suppression of COUP-TFII activity can slow disease progression.

Purpose of the Study:

• To identify and characterize a potent and specific inhibitor of COUP-TFII.
• To investigate the mechanism of action of the identified inhibitor.
• To evaluate the therapeutic potential of the inhibitor in preclinical models of prostate cancer.

Main Methods:

• High-throughput screening to identify COUP-TFII inhibitors.
• Biochemical assays to confirm inhibitor specificity and mechanism of action.
• In vivo studies using xenograft mouse models and patient-derived xenograft models of prostate cancer.

Main Results:

• A potent and specific COUP-TFII inhibitor was identified.
• The inhibitor directly binds to the COUP-TFII ligand-binding domain, disrupting interactions with co-regulators like FOXA1.
• The inhibitor suppressed COUP-TFII activity and demonstrated significant antitumor effects in prostate cancer models.

Conclusions:

• A novel, specific inhibitor of COUP-TFII has been developed.
• This inhibitor effectively blocks the oncogenic activity of COUP-TFII in prostate cancer.
• The identified inhibitor holds potential for treating prostate cancer and other diseases driven by COUP-TFII.